Mobia Medical (NASDAQ:MOBI) Posts Earnings Results

Mobia Medical (NASDAQ:MOBI) posted its earnings results on Tuesday. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27), FiscalAI reports. The firm had revenue of $13.51 million for the quarter. The firm’s quarterly revenue was up 102.4% on a year-over-year basis.

Here are the key takeaways from Mobia Medical’s conference call:

• Q2 revenue doubled year over year to $13.5 million, supported by broader Vivistim adoption, while gross margin increased to 83.2%. Management initiated 2026 revenue guidance of $54 million to $56 million, implying 69% to 75% growth.
• Commercial expansion continued, with average active territories rising 92% year over year to 35.5 and approximately 367 Vivistim units sold in the quarter. Management expects to add roughly four to five active territories in the second half while maintaining a measured expansion strategy.
• The May IPO generated approximately $134 million in net proceeds, leaving $177.1 million in cash and equivalents at quarter-end. The company plans to invest primarily in sales hiring, geographic expansion, patient awareness, and clinical evidence.
• CMS assigned Vivistim’s Category 1 CPT code to New Technology APC 1580 for 2026, representing Medicare reimbursement of approximately $45,000; however, the proposed 2027 payment classification is not final until November. Commercial payer coverage remains a multiyear development effort, though some insurers are already paying claims.
• Operating expenses grew faster than revenue, with SG&A up 85% to $26.9 million and R&D up 61% to $2.3 million. Net loss increased to $21.0 million, including a one-time, non-cash $4 million charge related to the conversion of convertible notes.

Mobia Medical Trading Down 2.0%

Shares of MOBI stock traded down $0.23 during trading hours on Thursday, reaching $11.29. 27,683 shares of the company’s stock were exchanged, compared to its average volume of 145,606. The business’s 50 day moving average price is $12.50. Mobia Medical has a fifty-two week low of $10.19 and a fifty-two week high of $15.29. The stock has a market cap of $375.39 million and a P/E ratio of -0.58.

Analyst Ratings Changes

Several brokerages recently commented on MOBI. BTIG Research reiterated a “buy” rating and set a $19.00 price target on shares of Mobia Medical in a report on Wednesday. Zacks Research raised Mobia Medical to a “hold” rating in a research report on Wednesday, June 3rd. Wall Street Zen raised Mobia Medical from a “sell” rating to a “hold” rating in a research report on Sunday, June 14th. JPMorgan Chase & Co. raised their target price on shares of Mobia Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Bank of America initiated coverage on Mobia Medical in a report on Tuesday, June 2nd. They issued a “buy” rating and a $16.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Mobia Medical has an average rating of “Moderate Buy” and an average target price of $20.75.

Insider Activity

In related news, CFO Nelson Bunker Curnes acquired 5,000 shares of the business’s stock in a transaction dated Tuesday, June 9th. The shares were purchased at an average price of $12.79 per share, for a total transaction of $63,950.00. Following the completion of the acquisition, the chief financial officer directly owned 366,997 shares in the company, valued at $4,693,891.63. The trade was a 1.38% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

About Mobia Medical

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.